TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Recommendation of “Hold” by Brokerages

TScan Therapeutics, Inc. (NASDAQ:TCRX) has received a consensus rating of “Hold” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $6.00.

Several brokerages have weighed in on TCRX. Wall Street Zen downgraded shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Wedbush reaffirmed an “outperform” rating and set a $5.00 price target on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Needham & Company LLC reiterated a “buy” rating and set a $6.00 price objective on shares of TScan Therapeutics in a report on Tuesday, June 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Friday, July 17th.

TScan Therapeutics Stock Performance

TCRX stock opened at $0.79 on Friday. TScan Therapeutics has a one year low of $0.79 and a one year high of $2.57. The firm has a market cap of $51.89 million, a price-to-earnings ratio of -0.83 and a beta of 1.04. The company has a debt-to-equity ratio of 0.34, a quick ratio of 6.65 and a current ratio of 6.65. The firm has a 50-day simple moving average of $0.98 and a two-hundred day simple moving average of $1.05.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.22). The firm had revenue of $0.98 million for the quarter, compared to the consensus estimate of $2.50 million. TScan Therapeutics had a negative net margin of 1,360.61% and a negative return on equity of 91.94%. On average, equities analysts forecast that TScan Therapeutics will post -1.11 EPS for the current fiscal year.

Institutional Investors Weigh In On TScan Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TCRX. Goldman Sachs Group Inc. boosted its holdings in TScan Therapeutics by 6.0% in the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock worth $235,000 after acquiring an additional 9,676 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of TScan Therapeutics by 8.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company’s stock valued at $417,000 after purchasing an additional 22,642 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of TScan Therapeutics in the 2nd quarter valued at approximately $78,000. Qube Research & Technologies Ltd acquired a new stake in TScan Therapeutics in the 2nd quarter worth approximately $99,000. Finally, Jane Street Group LLC acquired a new stake in TScan Therapeutics in the 2nd quarter worth approximately $309,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.